LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition

Abstract Background Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating f...

詳細記述

書誌詳細

主要な著者:	Jiunn-Chang Lin, Tun-Sung Huang, Yan-Bin Chen, Tung-Ying Chen, Pao-Shu Wu, Tsang-Pai Liu, Pei-Ming Yang
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2026-02-01
シリーズ:	Biology Direct
主題:	LDN-57444 Sorafenib Hepatocellular carcinoma Ferroptosis HDAC2
オンライン･アクセス:	https://doi.org/10.1186/s13062-026-00735-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!